Basdai Score Calculator
Calculate Bath Ankylosing Spondylitis Disease Activity Index from patient questionnaire. Enter values for instant results with step-by-step formulas.
Reviewed by Rahul Singh, Health & Wellness Specialist
Formula
BASDAI = (Q1 + Q2 + Q3 + Q4 + mean(Q5, Q6)) / 5
The BASDAI averages five disease domains: fatigue (Q1), spinal pain (Q2), peripheral joint pain (Q3), enthesitis (Q4), and morning stiffness (average of severity Q5 and duration Q6). Each question is scored 0-10. Score range: 0-10. Score >= 4 indicates active disease; < 4 indicates controlled disease.
Worked Examples
Example 1: Active AS Requiring Biologic Consideration
Problem:A patient with ankylosing spondylitis on maximum-dose NSAIDs reports: fatigue 7, spinal pain 8, joint pain 5, enthesitis 6, morning stiffness severity 7, morning stiffness duration 6.
Solution:Morning stiffness average: (7 + 6) / 2 = 6.5\nBASDAI = (7 + 8 + 5 + 6 + 6.5) / 5\nBASDAI = 32.5 / 5\nBASDAI = 6.5
Result:BASDAI: 6.5 | Active Disease (>= 4) | Eligible for biologic therapy if confirmed on repeat assessment
Example 2: Well-Controlled Disease on Current Therapy
Problem:A patient on adalimumab reports: fatigue 2, spinal pain 1, joint pain 1, enthesitis 0, morning stiffness severity 2, morning stiffness duration 1.
Solution:Morning stiffness average: (2 + 1) / 2 = 1.5\nBASDAI = (2 + 1 + 1 + 0 + 1.5) / 5\nBASDAI = 5.5 / 5\nBASDAI = 1.1
Result:BASDAI: 1.1 | Inactive / Well Controlled (< 4) | Continue current therapy, monitor every 3-6 months
Frequently Asked Questions
What is the BASDAI and what does it measure?
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a validated patient-reported outcome measure developed in 1994 at the Royal National Hospital for Rheumatic Diseases in Bath, England. It was designed specifically to assess disease activity in ankylosing spondylitis (now more broadly termed axial spondyloarthritis). The BASDAI captures six key domains of disease activity through patient self-assessment: fatigue, spinal pain, peripheral joint pain or swelling, enthesitis (areas of tenderness at tendon and ligament insertions), severity of morning stiffness, and duration of morning stiffness. Each domain is scored on a 0 to 10 visual analog scale, and the composite score provides a standardized measure of disease activity.
How is the BASDAI score calculated?
The BASDAI score is calculated from six questions, each rated on a numeric rating scale from 0 to 10. Questions 1 through 4 assess fatigue, spinal pain, peripheral joint pain/swelling, and enthesitis respectively. Questions 5 and 6 both relate to morning stiffness (severity and duration). The morning stiffness component is first averaged: (Q5 + Q6) / 2. Then the BASDAI is calculated as the mean of the first four questions plus the morning stiffness average, divided by five: BASDAI = (Q1 + Q2 + Q3 + Q4 + mean(Q5,Q6)) / 5. This produces a score from 0 to 10, where higher values indicate greater disease activity. The averaging of the two morning stiffness questions into a single component ensures equal weighting of the five disease domains.
What BASDAI score indicates active disease?
A BASDAI score of 4 or higher is the established threshold for active disease in ankylosing spondylitis and axial spondyloarthritis. This cutoff was determined through clinical validation studies and is used by the Assessment of SpondyloArthritis International Society (ASAS) and EULAR in their treatment guidelines as a key criterion for initiating biologic therapy. Specifically, a patient must have a BASDAI of 4 or higher on at least two consecutive assessments separated by at least 4 weeks to meet the eligibility criteria for biologic treatment. A score below 4 generally indicates that disease activity is adequately controlled, though clinical judgment should also consider functional impairment, inflammatory markers, and imaging findings.
How is the BASDAI used in treatment decisions for biologic therapy?
The BASDAI is a central criterion in the ASAS/EULAR recommendations for initiating biologic therapy in axial spondyloarthritis. The standard treatment pathway requires patients to first trial at least two different nonsteroidal anti-inflammatory drugs (NSAIDs) at maximal tolerated doses for a combined minimum of four weeks. If the BASDAI remains 4 or higher despite adequate NSAID therapy, the patient is considered to have failed conventional treatment and becomes eligible for biologic agents. First-line biologics include TNF inhibitors (adalimumab, etanercept, infliximab, certolizumab, golimumab) and IL-17 inhibitors (secukinumab, ixekizumab). Treatment response is assessed using the BASDAI50 criterion, which requires a 50 percent improvement or absolute decrease of 2 or more units.
References
Reviewed by Rahul Singh, Health & Wellness Specialist · Editorial policy